<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835754</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-CAR-121918</org_study_id>
    <nct_id>NCT03835754</nct_id>
  </id_info>
  <brief_title>Heart EXPAND Continued Access Protocol</brief_title>
  <official_title>Heart Expand Continued Access Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet
      current standard donor heart acceptance criteria for transplantation in this continued access
      protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To provide additional data evaluating the safety and effectiveness of the OCS™ Heart System
      to preserve and assess donor hearts that do not meet current standard donor heart acceptance
      criteria (as identified above) for transplantation to potentially improve donor heart
      utilization for transplantation at a range of transplant centers in the U.S. and to permit
      patients and physicians access to the OCS Heart System while a PMA application is under
      preparation and review.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patient survival post transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of severe PGD</measure>
    <time_frame>24 hours post heart transplant</time_frame>
    <description>Absence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patient and graft survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe PGD</measure>
    <time_frame>24 hours post transplant</time_frame>
    <description>Incidence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post heart transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor heart utilization rate</measure>
    <time_frame>24 hours post-transplant</time_frame>
    <description>The proportion of eligible donor hearts that were successfully transplanted after preservation and assessment on the OCS Heart System</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Patient survival at 6 and 12 months post-transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>Through 12 months post transplant</time_frame>
    <description>Incidence of primary graft failure requiring re-transplantation</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU stay</measure>
    <time_frame>Through hospital discharge, estimated to be 14 days</time_frame>
    <description>Duration of initial post-transplant ICU stay in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Through hospital discharge, estimated to be 30 days</time_frame>
    <description>Duration of initial post-transplant hospital stay in days</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>OCS Preservation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Heart System</intervention_name>
    <description>The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment</description>
    <arm_group_label>OCS Preservation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (DONOR):

        At least one of the following:

          -  Expected total cross-clamp time of ≥ 4 hours

          -  Expected total cross-clamp time of ≥ 2 hours PLUS one or more of the following risk
             factors Donor age 45-55 years, inclusive, with no coronary catheterization data; or
             Donor age ≥ 55 years; or Left ventricular septal or posterior wall thickness of &gt;12
             mm, but ≤ 16 mm; or Reported down time of ≥ 20 min, with stable hemodynamics at time
             of final assessment; or Left heart ejection fraction (EF) ≥ 40%, but ≤ 50% at time of
             acceptance of offer; or Donor angiogram with luminal irregularities with no
             significant CAD (≤ 50%); or History of carbon monoxide poisoning with good cardiac
             function at time of donor assessment; or Social history of alcoholism with good
             cardiac function at time of donor assessment; or History of diabetes without
             significant CAD (≤ 50%) on angiogram.

        Exclusion

          -  CAD with &gt; 50% stenosis on angiogram, or

          -  Cardiogenic shock or myocardial infarction, or

          -  EF consistently &lt; 40%, or

          -  Significant valve disease except for competent bicuspid aortic valve.

        Eligibility Criteria (RECIPIENT)

          -  Registered primary heart transplant candidate

          -  Age &gt;18 years old

          -  Written informed consent. Exclusion

          -  Prior solid organ or bone marrow transplant

          -  Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic
             renal insufficiency requiring dialysis

          -  Multi-organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Thottam</last_name>
      <phone>310-248-7132</phone>
      <email>maria.thottam@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Fardad Esmailan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Singleton, RN</last_name>
      <phone>407-303-7120</phone>
      <email>mailto:Christine.Singleton@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Scott Silvestry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Cardiovascular Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kami Drezek</last_name>
      <phone>617-724-2610</phone>
      <email>kdrezek@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David A D'Alessandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Thomas</last_name>
      <phone>612-863-7493</phone>
      <email>kari.m.thomas@allina.com</email>
    </contact>
    <investigator>
      <last_name>Karol Mudy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nyph/Cumc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Casalinova</last_name>
      <phone>919-613-5621</phone>
      <email>sarah.casalinova@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jacob Schroder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Johnson</last_name>
      <phone>614-292-5315</phone>
      <email>Michael.Johnson2@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Bryan Whitson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Slinger</last_name>
      <phone>615-875-2602</phone>
      <email>lisa.slinger@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Ashish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Silva</last_name>
      <phone>206-221-7833</phone>
      <email>silvacm8@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Koomalsingh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart preservation</keyword>
  <keyword>Beating heart transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

